Revvity Inc

Revvity Inc(RVTY)の株式分析

$154.710

+2.630 (+1.70%)終値時点

Loading chart…
高値
156.860
始値
151.910
出来高加重平均価格
153.47
出来高
2.37M
時価総額
13.04B
安値
148.830
売買代金
364.46M
EV/EBITDA(TTM)
21.21

Revvity, Inc. provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. It has specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. Its segments include Life Sciences and Diagnostics. The Life Sciences segment provides products and services targeted towards life sciences customers. The segment offers instruments, reagents, software, subscriptions, detection and imaging technologies, and others. The Diagnostics segment develops diagnostics, tools and applications focused on clinically oriented customers, especially within the areas of reproductive health and emerging market diagnostics. The segment offers instruments, reagents, assay platforms and software to hospitals, medical labs, clinicians and medical research professionals to help improve the health of families.

www.revvity.com

AI分析 of Revvity Inc (RVTY)

買い

Revvity Inc is a good buy right now due to its strong recent performance, with a current price of $154.18 and a year-to-date change of +57.09%. The stock is also showing positive momentum with an RSI of 61.707, indicating it is not overbought yet. Additionally, the forward P/E ratio of 24.15 suggests reasonable valuation compared to its growth prospects, especially with a gross margin of 57.13% in the latest quarter. However, the main risk is its high P/E ratio of 70.98, which indicates that the stock may be overvalued if growth does not meet expectations.

バリュエーション指標

Revvity Inc(RVTY)の現在の予想PERは24.15で、5年平均は22.13です。

予想PER

適正
5年平均 P/E
22.13
現在のP/E
24.15
割高
25.11
割安
19.14

予想EV/EBITDA

割高
5年平均 EV/EBITDA
18.11
現在のEV/EBITDA
21.21
割高
20.56
割安
15.66

予想PSR

割高
5年平均 P/S
4.58
現在のP/S
5.75
割高
5.29
割安
3.87

Alphio AI による RVTY の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%RVTY

$80.72

シナリオ価格

基

基本

基本 · 50%RVTY

$80.47

シナリオ価格

弱

弱気

弱気 · 25%RVTY

$65.23

シナリオ価格

RVTY を保有するクジラ

C

Campbell & Company, LP

+ を保有RVTY

+8.93%

3か月リターン

M

Meridiem Capital Partners LP

+ を保有RVTY

+5.65%

3か月リターン

E

EdgePoint Investment Group Inc.

+ を保有RVTY

+4.51%

3か月リターン

V

Vaughan Nelson Investment Management, L.P.

+ を保有RVTY

+2.68%

3か月リターン

P

Port Capital LLC

+ を保有RVTY

-1.53%

3か月リターン

イベントタイムライン

2026-09-24 (ET)

10:00:00

Everpure Stock Rises $20.86 to $130.51

08:30:00

Revvity Launches GSP T1D 3plex Detection Kit

2026-09-15 (ET)

10:00:00

Skyworks and Others See Notable Stock Gains

2026-09-09 (ET)

06:30:00

Revvity Acquires French Biotech Company HCD

2026-08-04 (ET)

06:30:00

FY26 Revenue Outlook Raised to $2.83B-$2.86B

ニュース

RVTY のよくある質問 — Alphio AI が回答

Revvity, Inc. provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. It has specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. Its segments include Life Sciences and Diagnostics. The Life Sciences segment provides products and services targeted towards life sciences customers. The segment offers instruments, reagents, software, subscriptions, detection and imaging technologies, and others. The Diagnostics segment develops diagnostics, tools and applications focused on clinically oriented customers, especially within the areas of reproductive health and emerging market diagnostics. The segment offers instruments, reagents, assay platforms and software to hospitals, medical labs, clinicians and medical research professionals to help improve the health of families. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).

Revvity Inc is a good buy right now due to its strong recent performance, with a current price of $154.18 and a year-to-date change of +57.09%. The stock is also showing positive momentum with an RSI of 61.707, indicating it is not overbought yet. Additionally, the forward P/E ratio of 24.15 suggests reasonable valuation compared to its growth prospects, especially with a gross margin of 57.13% in the latest quarter. However, the main risk is its high P/E ratio of 70.98, which indicates that the stock may be overvalued if growth does not meet expectations.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める